India’s third home vaccine: Corona vaccination for 12-18 age group will start soon, DCGI approves emergency use of Corbevax

Emergency use of Corbevax, the third indigenous corona vaccine made in the country, has also been approved. This vaccine has been prepared by Hyderabad-based pharmaceutical company Biological-E Limited. The special thing is that the Drugs Controller General of India (DCGI) has given permission to apply this vaccine to children between the age group of 12 to 18 years. With this, the way has been cleared for the vaccination of children between 12 to 14 years in the country to start soon. At present, Covaxin of Bharat Biotech Company is being applied to children in the age group of 15 to 18 years in the country.

Protein-based country’s first vaccine, Corbevax
Corbevax is a protein subunit vaccine. This is the first protein-based country’s first and the third corona vaccine developed in the country itself. Protein subunit vaccine means that it generates an immune response using a part of the virus rather than the whole virus. The company has claimed to be up to 80% effective during clinical trials of this vaccine.

The S protein of the corona virus is used in this vaccine. As soon as this S protein enters the body through the vaccine, the body’s immune system gets activated. This vaccine has been developed by Biological E in collaboration with Texas Children’s Hospital’s Vaccine Development Center.

How effective was the trial?
Biological E has tested the vaccine on more than 3 thousand people at more than 33 sites across the country. The results of the trial have revealed that the vaccine is more than 80% effective in preventing symptomatic infection against the delta strain. This vaccine will come in two doses and can be stored at 2 to 8 degree Celsius refrigerated temperature.